{"entity":{"type":"insider","cik":"0001918615","url":"/insider/0001918615","json_url":"/insider/0001918615.json","name":"Landau Jeffrey B","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2022-07-21","last":"2024-08-22","span_basis":"filed_date"},"name_variants":[{"name":"Landau Jeffrey B","source":"filing","n_filings":6,"first_seen":"2022-07-21","last_seen":"2024-08-22"}],"transactions":[{"id":2096344,"accession":"0001610717-24-000436","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-24-000436","line_url":"/filing/0001610717-24-000436#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4181.0,"shares_display":"4,181","price_per_share":1.2291,"price_display":"1.23","price_state":"stated","total_value":5138.8671,"total_display":"5,138.87","total_whole":"5,139","shares_owned_after":119056.0,"shares_owned_after_display":"119,056","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-20","filed_date":"2024-08-22","scope":"insider"},{"id":2048133,"accession":"0001610717-24-000175","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-24-000175","line_url":"/filing/0001610717-24-000175#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6562.0,"shares_display":"6,562","price_per_share":2.0855,"price_display":"2.09","price_state":"stated","total_value":13685.051,"total_display":"13,685.05","total_whole":"13,685","shares_owned_after":110060.0,"shares_owned_after_display":"110,060","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-19","filed_date":"2024-03-21","scope":"insider"},{"id":7982619,"accession":"0001610717-23-000421","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-23-000421","line_url":"/filing/0001610717-23-000421#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4077.0,"shares_display":"4,077","price_per_share":1.3805,"price_display":"1.38","price_state":"stated","total_value":5628.2985,"total_display":"5,628.30","total_whole":"5,628","shares_owned_after":86622.0,"shares_owned_after_display":"86,622","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-20","filed_date":"2023-12-22","scope":"insider"},{"id":8129373,"accession":"0001610717-23-000298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-23-000298","line_url":"/filing/0001610717-23-000298#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4119.0,"shares_display":"4,119","price_per_share":1.3003,"price_display":"1.30","price_state":"stated","total_value":5355.9357,"total_display":"5,355.94","total_whole":"5,356","shares_owned_after":76379.0,"shares_owned_after_display":"76,379","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-22","filed_date":"2023-09-22","scope":"insider"},{"id":7828229,"accession":"0001140361-23-012615","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-23-012615","line_url":"/filing/0001140361-23-012615#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1477.0,"shares_display":"1,477","price_per_share":1.9792,"price_display":"1.98","price_state":"stated","total_value":2923.2784,"total_display":"2,923.28","total_whole":"2,923","shares_owned_after":69248.0,"shares_owned_after_display":"69,248","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-16","filed_date":"2023-03-20","scope":"insider"},{"id":6496367,"accession":"0001567619-22-014300","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-014300","line_url":"/filing/0001567619-22-014300#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001918615","owner_name":"Landau Jeffrey B","owner_display_name":"Landau Jeffrey B","owner_url":"/insider/0001918615","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4206.0,"shares_display":"4,206","price_per_share":1.4222,"price_display":"1.42","price_state":"stated","total_value":5981.7732,"total_display":"5,981.77","total_whole":"5,982","shares_owned_after":30725.0,"shares_owned_after_display":"30,725","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-20","filed_date":"2022-07-21","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Officer (Chief Business Officer)","n_filings":6,"first_seen":"2022-07-21","last_seen":"2024-08-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001918615","retrieved_at":"2026-08-27T15:35:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}